Evidence map›Paper›PMID 35906512›Full record

ArticleMolecular imaging and biology2023

Imaging the Alternatively Spliced D Domain of Tenascin C in a Preclinical Model of Inflammatory Bowel Disease.

Liang Zhang, Yuzhen Wang, Kristoff T Homan, Stephanie M Gaudette, Andrew J McCluskey, Ying Chan, Joanne Murphy, Mary Abdalla, Christine M Nelson, Victor Z Sun and 5 more

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Engineering cytokine therapeutics.Nature reviews bioengineering · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Liang ZhangAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA. liang.zhang@abbvie.com.ORCID 0000-0001-5766-2302
Yuzhen WangAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Kristoff T HomanBristol Myers Squibb, 100 Binney St, Cambridge, MA, 02142, USA.
Stephanie M GaudetteWorcester Technical High School, 1 Officer Manny Familia Wy, Worcester, MA, 01605, USA.
Andrew J McCluskeyAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Ying ChanAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Joanne MurphyAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Mary AbdallaAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Christine M NelsonAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Victor Z SunAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Jamie E EricksonAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Heather L KnightAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Anca ClabbersAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Annette J Schwartz StermanAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
Soumya MitraAbbVie Bioresearch Center, 100 Research Dr, Worcester, MA, 01605, USA.
AbbVie (United States) · USBristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo image colon-expressed alternatively spliced D domain of tenascin C in preclinical colitis models using near infrared (NIR)-labeled targeted molecular imaging agents. PROCEDURES: A human IgG1 with nanomolar binding affinity specific to the alternatively spliced D domain of tenascin C was generated. Immunohistochemistry identified disease-specific expression of this extracellular matrix protein in the colon of mice given dextran sulfate sodium in the drinking water. The antibody reagent was labeled with the NIR fluorophore IRDye 800CW via amine chemistry and intravenously dosed to evaluate in vivo targeting specificity. Increasing doses of imaging agent were given to estimate the saturating dose.

resultsThe NIR-labeled proteins successfully targeted colonic lesions in a murine model of colitis. Co-administration of a molar excess competing unlabeled dose reduced normalized uptake in diseased colon by > 70%. Near infrared ex vivo images of colon resected from diseased animals showed saturation at doses exceeding 1 nmol and was confirmed with additional quantitative ex vivo biodistribution. Cellular-level specificity and protein stability were assessed via microscopy.

conclusionsOur imaging data suggest the alternatively spliced D domain of tenascin C is a promising target for delivery-based applications in inflammatory bowel diseases.

Indexed as

ColitisInflammatory Bowel DiseasesAnimalsHumansMiceTenascinTissue DistributionTenascinECM imagingInflammatory bowel diseaseNear infrared molecular imagingTargeted delivery

Identifiers

PMID35906512
PMCPMC10006278
OpenAlexW4288693542

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read30
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.